Business Context and Reporting Period
This Form 8-K Current Report, dated May 10, 2022, details significant executive leadership changes at Zentalis Pharmaceuticals, Inc. (ZNTL). The report covers the resignation of the former CEO and Chairman and the appointment of a new CEO and interim leadership effective May 10, 2022.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The only specific financial data disclosed relates to executive compensation and a prior service agreement:
- Tempus Services Fees: Approximately $1.0 million in fees were incurred for services performed by Tempus Labs for the year ended December 31, 2021.
- New CEO Compensation (Dr. Kimberly Blackwell):
- Annual Base Salary: $680,000.
- Target Annual Bonus: 60% of base salary ($408,000).
- Sign-on Bonus: $250,000 (subject to repayment if resigned without good reason within one year).
- Equity Grants: Options to purchase 3.0% of outstanding common stock (time-based vesting) and 0.75% (performance/change-in-control vesting).
- Former CEO Severance (Dr. Anthony Y. Sun):
- Lump sum payment equal to 18 months' base salary plus prorated 2022 target bonus.
- 18 months of COBRA premiums paid by the Company.
- Accelerated vesting of restricted stock units by February 11, 2023, and stock options by February 11, 2025.
Material Changes
The primary material change is the complete turnover of the Company's top executive leadership:
- Resignation: Anthony Y. Sun, M.D., resigned as President, CEO, Director, and Chairman of the Board effective May 10, 2022.
- Interim Leadership: Kevin M. Bunker, Ph.D. (COO), was designated as interim Principal Executive Officer. David M. Johnson was appointed Chairman of the Board.
- New CEO Appointment: Kimberly Blackwell, M.D., was appointed President and CEO, with employment expected to commence on or about May 16, 2022. She will continue as a Director but will step down from the Nominating and Corporate Governance Committee.
- Board Committee Change: Karan S. Takhar will cease serving on the Audit Committee effective May 18, 2022.
Outlook, Risks, and Contingencies
Management Commentary and Risks:
- Related Party Transaction: The filing notes a potential conflict of interest regarding Dr. Blackwell's prior role as Chief Medical Officer at Tempus Labs, a company with which Zentalis has a Master Services Agreement. Dr. Blackwell resigned from Tempus effective May 16, 2022, but will remain a consultant.
- Retention Risk: The new CEO's sign-on bonus is subject to clawback if she resigns without good reason within the first year.
- Change in Control Provisions: Dr. Blackwell's employment agreement includes enhanced severance (150% of target bonus) and full stock option vesting in the event of a termination following a change in control.
Unusual Items: The filing does not disclose unusual financial items or litigation contingencies beyond the standard executive transition agreements.
Investor Verification Checklist
- Verify the exact commencement date of Dr. Blackwell's employment and the associated stock option grant date to determine the exercise price.
- Review the full text of the Employment Agreement (Exhibit 10.1) and Release Agreement (Exhibit 10.2) for specific definitions of "cause" and "good reason."
- Assess the impact of Dr. Blackwell's continued consulting relationship with Tempus Labs on the existing Master Services Agreement.
- Confirm the total cash outflow for Dr. Sun's severance package once his final base salary and bonus calculations are finalized.
- Monitor the composition of the Audit Committee following Karan S. Takhar's departure.